Jane Street’s Nurix Therapeutics NRIX Stock Holding History

Jane Street’s Portfolio NRIX Stock Details NRIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.23M	Buy	+50,900	New	+$867K	﹤0.01%	6095
2026 Q1	–	Sell	-15,200	Closed	-$288K	–	12544
2025 Q4	$288K	Buy	+15,200	New	+$218K	﹤0.01%	8924

Other funds holding NRIX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

VPC

Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Jane Street's NRIX Position: Q2 2026 in Review

Jane Street sold out of Nurix Therapeutics (NRIX) in Q2 2026, closing a stake of 12,273 shares — an estimated $209K sold.

Jane Street first reported a position in NRIX in Q4 2022 and held it in 10 quarters. The position peaked at $4.18M in Q2 2024. 211 funds tracked by Wall St. Rank hold NRIX as of Q2 2026.

Jane Street reported no remaining Nurix Therapeutics position as of Q2 2026 after selling out during the quarter.
Jane Street sold 12,273 Nurix Therapeutics shares in Q2 2026, an estimated $209K.
Jane Street first reported a position in Nurix Therapeutics in Q4 2022 and held it in 10 quarters.
Jane Street's Nurix Therapeutics position peaked at $4.18M in Q2 2024.
211 funds tracked by Wall St. Rank held Nurix Therapeutics as of Q2 2026.

Based on Jane Street's 13F filing for Q2 2026, filed 14 Aug 2026.